Sino Biopharmaceutical Statistics

Total Valuation

FRA:SMZ1 has a market cap or net worth of EUR 9.81 billion. The enterprise value is 10.48 billion.

Market Cap	9.81B
Enterprise Value	10.48B

Important Dates

The next estimated earnings date is Monday, August 25, 2025.

Earnings Date	Aug 25, 2025
Ex-Dividend Date	Jun 16, 2025

Share Statistics

Current Share Class	17.88B
Shares Outstanding	n/a
Shares Change (YoY)	-2.36%
Shares Change (QoQ)	-1.25%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	8.84B

Valuation Ratios

The trailing PE ratio is 21.18 and the forward PE ratio is 24.99.

PE Ratio	21.18
Forward PE	24.99
PS Ratio	2.57
PB Ratio	1.73
P/TBV Ratio	2.41
P/FCF Ratio	13.11
P/OCF Ratio	11.21
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 12.99, with an EV/FCF ratio of 14.01.

EV / Earnings	22.63
EV / Sales	3.09
EV / EBITDA	12.99
EV / EBIT	15.67
EV / FCF	14.01

Financial Position

The company has a current ratio of 1.26, with a Debt / Equity ratio of 0.23.

Current Ratio	1.26
Quick Ratio	1.11
Debt / Equity	0.23
Debt / EBITDA	1.39
Debt / FCF	1.72
Interest Coverage	19.66

Financial Efficiency

Return on equity (ROE) is 11.82% and return on invested capital (ROIC) is 7.02%.

Return on Equity (ROE)	11.82%
Return on Assets (ROA)	5.62%
Return on Invested Capital (ROIC)	7.02%
Return on Capital Employed (ROCE)	12.65%
Revenue Per Employee	156,688
Profits Per Employee	18,997
Employee Count	24,379
Asset Turnover	0.45
Inventory Turnover	2.44

Taxes

In the past 12 months, FRA:SMZ1 has paid 65.23 million in taxes.

Income Tax	65.23M
Effective Tax Rate	9.34%

Stock Price Statistics

The stock price has increased by +74.52% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+74.52%
50-Day Moving Average	0.48
200-Day Moving Average	0.42
Relative Strength Index (RSI)	57.47
Average Volume (20 Days)	7,313

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, FRA:SMZ1 had revenue of EUR 3.82 billion and earned 463.14 million in profits. Earnings per share was 0.03.

Revenue	3.82B
Gross Profit	3.11B
Operating Income	767.68M
Pretax Income	698.37M
Net Income	463.14M
EBITDA	912.13M
EBIT	767.68M
Earnings Per Share (EPS)	0.03

Full Income Statement

Balance Sheet

The company has 1.96 billion in cash and 1.29 billion in debt, giving a net cash position of 675.86 million.

Cash & Cash Equivalents	1.96B
Total Debt	1.29B
Net Cash	675.86M
Net Cash Per Share	n/a
Equity (Book Value)	5.66B
Book Value Per Share	0.24
Working Capital	678.71M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 875.39 million and capital expenditures -127.05 million, giving a free cash flow of 748.34 million.

Operating Cash Flow	875.39M
Capital Expenditures	-127.05M
Free Cash Flow	748.34M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 81.51%, with operating and profit margins of 20.10% and 12.12%.

Gross Margin	81.51%
Operating Margin	20.10%
Pretax Margin	18.28%
Profit Margin	12.12%
EBITDA Margin	23.88%
EBIT Margin	20.10%
FCF Margin	19.59%

Dividends & Yields

This stock pays an annual dividend of 0.00, which amounts to a dividend yield of 0.78%.

Dividend Per Share	0.00
Dividend Yield	0.78%
Dividend Growth (YoY)	-37.54%
Years of Dividend Growth	n/a
Payout Ratio	17.42%
Buyback Yield	2.36%
Shareholder Yield	3.16%
Earnings Yield	4.72%
FCF Yield	7.63%

Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on July 20, 2020. It was a forward split with a ratio of 1.5.

Last Split Date	Jul 20, 2020
Split Type	Forward
Split Ratio	1.5

Scores

FRA:SMZ1 has an Altman Z-Score of 2.75 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.75
Piotroski F-Score	6